

# CHINA MEDICAL (INTERNATIONAL) GROUP LIMITED

(Company Registration No. 200505118M)

---

## PROPOSED RENOUNCEABLE AND NON-UNDERWRITTEN RIGHTS CUM WARRANTS ISSUE – RECEIPT OF LISTING AND QUOTATION NOTICE

---

The Board of Directors (“**Directors**”) of China Medical (International) Group Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) refers to the announcements made by the Company on 31 March 2017 and 7 June 2017 (the “**Previous Announcements**”) in relation to the proposed renounceable and non-underwritten rights issue of up to 10,107,788,721 new ordinary shares of the Company (the “**Rights Shares**”) with up to 10,107,788,721 free detachable warrants (the “**Warrants**”), on the basis of three (3) Rights Shares for every one (1) existing ordinary share (the “**Shares**”) of the Company held by entitled shareholders as at the books closure date to be determined, and one (1) Warrant for every one (1) Rights Shares subscribed, fractional entitlements to be disregarded (the “**Rights cum Warrants Issue**”).

Unless otherwise defined, all capitalised terms used herein shall bear the same meanings as ascribed to them in the Previous Announcements.

### 1. LISTING AND QUOTATION NOTICE

The Directors wish to announce that the Company’s Sponsor (as defined below) has, on 15 September 2017, obtained the listing and quotation notice (the “**LQN**”) from the SGX-ST in respect of the listing and quotation of:

- (a) up to 10,107,788,721 Rights Shares;
- (b) up to 10,107,788,721 Warrants;
- (c) up to 10,107,788,721 New Shares;

on SGX-ST Catalist, subject to the following:

- (i) compliance with the listing requirements of the SGX-ST; and
- (ii) submission of a confirmation that a sufficient spread in the Warrants as required under Rule 826 of the Listing Manual is complied with.

Please note that the LQN is not an indication of the merits of the Rights cum Warrants Issue, the Rights Shares, the Warrants, the New Shares, the Company, its subsidiaries and their securities.

### 2. RESPONSIBILITY STATEMENT

The Directors collectively and individually accept full responsibility for the accuracy of the information given in this announcement and confirm after making all reasonable enquiries, that to the best of their knowledge and belief, this announcement constitutes full and true disclosure of all material facts about the Rights cum Warrants Issue, the Company and its subsidiaries, and the Directors are not aware of any facts the omission of which would make any statement in this announcement misleading. Where information in the announcement has been extracted from published or otherwise publicly available sources or obtained from a

named source, the sole responsibility of the Directors has been to ensure that such information has been accurately and correctly extracted from those sources and/or reproduced in the announcement in its proper form and context.

**By Order of the Board**  
**17 September 2017**

---

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor") for compliance with the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement.*

*This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Lance Tan, Director, Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).*